CorMedix, Inc. is a pharmaceutical company based in the United States, with a medium risk rating score of 29.3. Specializing in developing and selling therapeutic products for infectious and inflammatory diseases, CorMedix's main focus is on the commercialization of its flagship product, DefenCath, in key markets including the U.S. and beyond. The company's ESG score reflects its commitment to sustainability and governance practices.